Clinical utility of a blood-based BRAF V600E mutation assay in melanoma

BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treatment decisions. Blood BRAF(V600E) detection and qu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Panka, David J, Buchbinder, Elizabeth, Giobbie-Hurder, Anita, Schalck, Aislyn P, Montaser-Kouhsari, Laleh, Sepehr, Alireza, Lawrence, Donald P., McDermott, David F., Cohen, Rachel, Carlson, Alexander, Wargo, Jennifer A, Merritt, Ryan, Seery, Virginia J., Hodi, F. Stephen, Gunturi, Anasuya, Fredrick, Dennie, Atkins, Michael B., Iafrate, A. John, Flaherty, Keith T., Mier, James W, Sullivan, Ryan J
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258469/
https://ncbi.nlm.nih.gov/pubmed/25319388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0349
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares